Mammalian steroidogenic cytochrome P450 enzymes (Steroidogenic CYPs)

Mammalian steroidogenic cytochrome P450 enzymes are a specialized class of heme-containing monooxygenases that catalyze the rate-limiting steps in the biosynthesis of steroid hormones from cholesterol (Miller & Auchus, 2011, Endocr Rev). This group includes key enzymes such as CYP11A1 (side-chain cleavage), CYP17A1 (17α-hydroxylase/17,20-lyase), CYP19A1 (aromatase), and the CYP11B subfamily, which are primarily expressed in the adrenal cortex, gonads, and placenta (Payne & Hales, 2004, Endocr Rev). These enzymes are essential for maintaining physiological homeostasis, regulating processes such as glucose metabolism, salt balance, and sexual development through the production of glucocorticoids, mineralocorticoids, and sex steroids (UniProt P11712, P11511). Pathological overactivity or genetic deficiencies in these enzymes are linked to conditions like Cushing's syndrome, congenital adrenal hyperplasia, and hormone-dependent cancers (StatPearls, "Congenital Adrenal Hyperplasia"). As therapeutic targets, they are modulated by various drugs; for example, aromatase inhibitors like letrozole are standard care for estrogen receptor-positive breast cancer, while CYP17A1 inhibitors like abiraterone are used to treat advanced prostate cancer (FDA Label, Zytiga). Pharmacological intervention requires careful management to avoid side effects like adrenal insufficiency or off-target endocrine disruption (PubMed: 21303910). These enzymes are located either in the mitochondria or the endoplasmic reticulum, requiring specific electron donor systems like adrenodoxin or NADPH-cytochrome P450 reductase (Miller, 2005, J Clin Invest). Their central role in human physiology makes them one of the most important clusters of enzymes in endocrinology and oncology.

Other names

Steroidogenic P450sCytochrome P450 steroid hydroxylasesSteroid hydroxylasesSteroidogenic CYPsAdrenal and gonadal P450 enzymes

Drugs targeting these enzymes typically act as competitive or mechanism-based (irreversible) inhibitors that bind to the heme iron or the active site, thereby blocking the conversion of precursor steroids into active hormones such as androgens, estrogens, or corticosteroids (Miller & Auchus, 2011, Endocr Rev).